Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Drug toxicity: Idiosyncratic Reactions

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...

Drug Toxicity: Dose-Dependent Reactions

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

McSART: an iterative model-based, motion-compensated SART algorithm for CBCT reconstruction.

Physics in medicine and biology·2019

Same author

A prospective gating method to acquire a diverse set of free-breathing CT images for model-based 4DCT.

Physics in medicine and biology·2018

Same author

SU-E-J-210: Lung Tumor Target Volume Contours on EPID Cine Mode Images.

Medical physics·2017

Same author

3D fluoroscopic image estimation using patient-specific 4DCBCT-based motion models.

Physics in medicine and biology·2015

Same author

Letter: antibiotic dose adjustment in patients with advanced liver disease--authors' reply.

Alimentary pharmacology & therapeutics·2013

Same author

Review article: prescribing medications in patients with cirrhosis - a practical guide.

Alimentary pharmacology & therapeutics·2013

Search research articles

Related Experiment Video

Updated: Jul 19, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Drug-induced liver disease.

W Mayoral¹, J H Lewis

¹Division of Gastroenterology, Georgetown University Medical Center, Washington, DC 20007, USA.

Current Opinion in Gastroenterology

|October 7, 2006

Summary

This review covers drug-induced liver injury (DILI), including its natural history, placebo effects, and newly identified causes. It also explores hepatoprotective strategies for preventing and treating liver damage from medications like acetaminophen.

Area of Science:

Hepatology
Pharmacology
Toxicology

Background:

Drug-induced liver injury (DILI) is a significant clinical concern.
Understanding the spectrum of DILI, from new agents to established drugs, is crucial.
Placebo effects on liver enzymes warrant careful consideration in clinical trials.

Purpose of the Study:

To provide a comprehensive overview of DILI.
To review newly identified and established drug hepatotoxicity.
To discuss the emerging field of hepatoprotection.

Main Methods:

Literature review and synthesis of current research.
Analysis of clinical and experimental data on DILI.
Examination of hepatoprotective agents and their mechanisms.

More Related Videos

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

Published on: June 17, 2016

Related Experiment Videos

Last Updated: Jul 19, 2026

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat

Published on: June 17, 2016

Main Results:

Detailed natural history of DILI.
Discussion of placebo-related elevations in liver enzymes.
Identification of novel and established drugs causing hepatic injury.
Review of hepatoprotective agents, focusing on acetaminophen.

Conclusions:

DILI remains a complex challenge in clinical practice.
Hepatoprotection offers promising avenues for managing drug-induced liver damage.
Continued research is vital for improving DILI prevention and treatment.